{"entity":{"id":"nct07724223","kind":"trial","name":"Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC","aka":[],"tldr":"A phase 2 trial of fruquintinib and cetuximab in colorectal cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.","summary":"Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC is a phase 2, interventional study registered as NCT07724223 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 46 participants, started 2026-01-16 and due to reach its primary completion in 2028-10-01. Interventions recorded: Fruquintinib plus Cetuximab-beta. Conditions listed: Metastatic Colorectal Cancer (CRC). Primary outcome: Objective Response Rate (ORR). Colorectal eligibility wording from the registry: \"Histologically confirmed metastatic or advanced colorectal adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07724223","url":"https://clinicaltrials.gov/study/NCT07724223"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors","monoclonal-antibody"],"targets":[],"drugs":["fruquintinib","cetuximab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07724223","phase":"2","setting":"A Phase II Study of Fruquintinib Combined With Anti-EGFR Monoclonal Antibody in Third-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","enrolled":46,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07724223/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}